Published in J Allergy Clin Immunol on March 01, 1996
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest (1997) 1.22
Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol (2007) 1.09
Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy. J Allergy Clin Immunol (2014) 0.93
Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine (2011) 0.87
Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology (2002) 0.81
Sensitization to timothy grass pollen allergenic molecules in children. Multidiscip Respir Med (2013) 0.76
New strategies for allergen T cell epitope identification: going beyond IgE. Int Arch Allergy Immunol (2014) 0.76
Poor association of allergen-specific antibody, T- and B-cell responses revealed with recombinant allergens and a CFSE dilution-based assay. Allergy (2015) 0.75
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol (1984) 2.70
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst (1991) 2.50
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia (2008) 2.44
A shared antigenic determinant between natural killer cells and nervous tissue. Nature (1984) 2.24
Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J (2010) 2.19
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy (2003) 2.08
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity (1995) 2.07
Revised analysis of aadA2 gene of plasmid pSa. Antimicrob Agents Chemother (1994) 2.03
Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry (2001) 1.93
The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J (1989) 1.93
Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry (1999) 1.90
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy (1997) 1.80
Microinjected profilin affects cytoplasmic streaming in plant cells by rapidly depolymerizing actin microfilaments. Curr Biol (1994) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy (2002) 1.63
Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science (1991) 1.62
The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol (1995) 1.59
Basophils are not the key antigen-presenting cells in allergic patients. Allergy (2012) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
The profilin multigene family of maize: differential expression of three isoforms. Plant J (1993) 1.56
Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy (2000) 1.55
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy (2004) 1.55
Transcription of a zein gene introduced into sunflower using a Ti plasmid vector. EMBO J (1984) 1.54
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med (1996) 1.51
The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy (1999) 1.51
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res (2001) 1.48
Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy (2014) 1.45
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
Formaldehyde-induced anaphylaxis after dental treatment? Contact Dermatitis (1991) 1.44
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol (2004) 1.43
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol (2009) 1.43
Marker of peripheral blood granulocytes and monocytes of man recognized by two monoclonal antibodies VEP8 and VEP9 involves the trisaccharide 3-fucosyl-N-acetyllactosamine. Eur J Immunol (1983) 1.41
Venoconstrictive thigh cuffs impede fluid shifts during simulated microgravity. Aviat Space Environ Med (1998) 1.40
Effects of nimodipine on regional blood flow in heart and brain during cardiopulmonary resuscitation in pigs. Anesth Analg (1994) 1.39
Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. Wien Klin Wochenschr (1998) 1.39
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Profilins constitute a novel family of functional plant pan-allergens. J Exp Med (1992) 1.35
A beta 1-integrin receptor for fibronectin in human kidney glomeruli. Am J Pathol (1989) 1.34
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest (2009) 1.32
Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol (1996) 1.30
Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest (2008) 1.29
Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol (1998) 1.28
Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J (1998) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. Biochem Biophys Res Commun (1995) 1.25
A monoclonal antibody against a surface antigen shared by human large granular lymphocytes and granulocytes. J Immunol (1982) 1.24
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest (1997) 1.22
Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J (2001) 1.21
IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy (1989) 1.21
Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol (1989) 1.21
Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy (2010) 1.20
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest (1995) 1.20
The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure (1997) 1.18
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res (2001) 1.17
Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol (1999) 1.17
Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma (2000) 1.16
Is there a role for continuation phase cognitive therapy for depressed outpatients? J Consult Clin Psychol (1998) 1.16
Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy (2008) 1.16